Drug profile · INN
palivizumab
SYNAGIS
palivizumab (SYNAGIS) is a fusion glycoprotein f0 inhibitor. Current US regulatory status: approved.
FDA: approved EMA: approved Antiinfectives for systemic use (J06) J06BD01
US status approved
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — palivizumab
- US status
- approved
- Class
- Antiinfectives for systemic use (J06)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
palivizumab (SYNAGIS) is a fusion glycoprotein f0 inhibitor. Current US regulatory status: approved.
Key facts
INN palivizumab
Brand SYNAGIS
Mechanism Fusion glycoprotein F0 inhibitor
Target Fusion glycoprotein F0
Therapeutic class Antiinfectives for systemic use (J06)
Formulation VIAL
ATC code J06BD01
Mechanism of action
Fusion glycoprotein F0 inhibitor
Primary target: Fusion glycoprotein F0
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is palivizumab?
palivizumab (SYNAGIS) is a fusion glycoprotein f0 inhibitor. Current US regulatory status: approved.
What is the brand name for palivizumab?
SYNAGIS is a marketed brand name for palivizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of palivizumab?
palivizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.